Last reviewed · How we verify
Placebo of DWJ1252
Placebo of DWJ1252 is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development.
This is a placebo control and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of DWJ1252 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo formulation for DWJ1252, this product is inert and serves as a control comparator in clinical trials. It is designed to match the appearance and administration route of the active drug to maintain blinding in phase 3 studies.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PHASE3)
- Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of DWJ1252 CI brief — competitive landscape report
- Placebo of DWJ1252 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about Placebo of DWJ1252
What is Placebo of DWJ1252?
How does Placebo of DWJ1252 work?
Who makes Placebo of DWJ1252?
What development phase is Placebo of DWJ1252 in?
Related
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
- Compare: Placebo of DWJ1252 vs similar drugs
- Pricing: Placebo of DWJ1252 cost, discount & access